logo
Plus   Neg
Share
Email

Enerplus Slips To Loss In Q4

Enerplus Corp. (ERF,ERF.TO) reported a fourth quarter net loss of C$429.1 million compared to net income of C$249.3 million in the same period in 2018, primarily due to a C$451.1 million non-cash goodwill impairment related to the company's Canadian reporting unit as a result of the cumulative impact of Canadian asset divestments, the shut-in of uneconomic natural gas production in Tommy Lakes and lower forecasted commodity prices. Loss per share was $1.93, compared to earnings per share of $1.02 in the prior year.

Earnings were further impacted by a C$28.8 million loss on commodity derivative instruments in the fourth quarter of 2019 compared to a C$253.7 million gain in the same period in 2018.

Excluding the goodwill impairment and certain other non-cash or non-recurring items, fourth quarter adjusted net income was C$34.4 million, compared to C$102.2 million in the same period in 2018. The reduction in adjusted net income was primarily due to higher operating expenses and a realized foreign exchange loss in the fourth quarter of 2019.

Total production for the fourth quarter of 2019 was 107,436 BOE per day, a 10% increase from the same period in 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT